Kunming, China, October 27, 2016
KBI establishes Parkinson Disease (PD) Models through:
1. Systemic MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Administration
· Intramuscular administration of MPTP
· Intravenous administration of MPTP
· Systemic bilateral symptom model

2. Local CNS MPTP Administration
· Stereotaxic intra-nigral injection
· Specific delivery of MPTP to the substantia nigra (SN), unilateral or bilateral
· Eliminate systemic non-PD toxicity
· Targeted unilateral or bilateral symptom model

PD Model evaluation:
1. Behavioral analysis: (Kurlan’s scale)
2. Imaging analysis:
MRI (Structural change)
SPECT (Functional change)
3. Biochemical analysis: dopamine & metabolites
4. L-DOPA treatment: positive drug to relieve the PD symptoms
5. Pathological analysis: Immunohistochemistry (Tyrosine Hydroxylase neuron staining)

Contact us if you need more information.